Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Susan Siegel, David Singer, George Weinstock, Timothy Triche, Gene Myers


Susan Siegel has resigned from Pacific Biosciences' board of directors and David Singer said that he will not stand for re-election to the board at the company's 2013 annual meeting of stockholders.

Siegel has been on the company's board since 2006. She is CEO of Healthymagination, a General Electric company. She has previously served on the board of directors for a number of companies, including Navigenics, RainDance Technologies, and Affymetrix.

Singer has also been on PacBio's board since 2006. Previously, he was founding president and CEO of Affymetrix. Currently, he is a limited partner at private investment firm Maverick Capital.

Real Time Genomics has formed a scientific advisory board that includes George Weinstock, associate director of the Genome Institute at Washington University; Timothy Triche, director of the Center for Personalized Medicine at Children's Hospital Los Angeles and the associate director of the Pediatric Institute of Molecular Medicine at Phoenix Children's Hospital; and Gene Myers, director of the Center for Systems Biology at the Max Planck Institute.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.